Lin Wang Selected Research

Squamous Cell Carcinoma of Head and Neck

12/2023	The role of PDIA3 in oral squamous cell carcinoma and its value as A diagnostic and prognostic biomarker.
12/2023	Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.
2/2023	Bioinformatics analyses proposed xenotropic and polytropic retrovirus receptor 1 as a potential diagnostic and prognostic biomarker and immunotherapeutic target in head and neck squamous cell carcinoma.
1/2023	Bioinformatics analysis of CUL2/4A/9 and its function in head and neck squamous cell carcinoma.
1/2023	Corrigendum: Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study.
1/2023	Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study.
1/2023	Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study.
5/2022	Bone morphogenetic protein receptor 1α promotes osteolytic lesion of oral squamous cell carcinoma by SHH-dependent osteoclastogenesis.
4/2022	Histone methyltransferase KMT2D cooperates with MEF2A to promote the stem-like properties of oral squamous cell carcinoma.
10/2021	First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lin Wang Research Topics

Disease

720	Neoplasms (Cancer) 07/2024 - 11/2002
193	Infections 05/2024 - 12/2002
183	Inflammation (Inflammations) 05/2024 - 09/2002
131	Neoplasm Metastasis (Metastasis) 02/2024 - 08/2008
79	Fibrosis (Cirrhosis) 04/2024 - 12/2002
76	Hepatocellular Carcinoma (Hepatoma) 04/2023 - 02/2003
75	Breast Neoplasms (Breast Cancer) 02/2024 - 12/2002
70	Carcinogenesis 03/2024 - 05/2002
63	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2024 - 01/2010
62	Wounds and Injuries (Trauma) 05/2024 - 07/2003
62	COVID-19 04/2024 - 01/2020
57	Lung Neoplasms (Lung Cancer) 05/2024 - 08/2008
56	Hypoxia (Hypoxemia) 12/2024 - 06/2007
53	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 09/2007
52	Carcinoma (Carcinomatosis) 11/2023 - 11/2002
51	Squamous Cell Carcinoma of Head and Neck 12/2023 - 04/2005
50	Pain (Aches) 03/2024 - 11/2007
50	Stomach Neoplasms (Stomach Cancer) 06/2023 - 12/2004
49	Nasopharyngeal Carcinoma 02/2024 - 01/2013
47	Stroke (Strokes) 05/2024 - 01/2013
47	Prostatic Neoplasms (Prostate Cancer) 01/2024 - 10/2006
41	Hypertension (High Blood Pressure) 12/2023 - 02/2004
40	Alzheimer Disease (Alzheimer's Disease) 04/2024 - 02/2004
38	Glioma (Gliomas) 02/2024 - 04/2013
36	Reperfusion Injury 02/2024 - 01/2004
35	Body Weight (Weight, Body) 01/2024 - 11/2006
35	Ischemia 08/2023 - 01/2004
34	Adenocarcinoma 02/2023 - 04/2008
33	Rectal Neoplasms (Rectal Cancer) 02/2024 - 05/2010
33	Adenocarcinoma of Lung 01/2023 - 04/2010
32	Disease Progression 04/2024 - 03/2011
31	Myocardial Infarction 10/2023 - 11/2004
30	Heart Failure 05/2024 - 12/2003
29	Ischemic Stroke 05/2024 - 01/2014
29	Cardiovascular Diseases (Cardiovascular Disease) 02/2024 - 12/2009
29	Atherosclerosis 12/2023 - 01/2005
27	Bacterial Infections (Bacterial Infection) 03/2024 - 04/2009
27	Ovarian Neoplasms (Ovarian Cancer) 09/2023 - 12/2002
26	Type 2 Diabetes Mellitus (MODY) 12/2023 - 03/2005
26	Colonic Neoplasms (Colon Cancer) 01/2023 - 04/2004
26	Arthritis (Polyarthritis) 01/2023 - 07/2011
25	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2024 - 11/2002
25	Lymphatic Metastasis 01/2023 - 04/2008
24	Diabetes Mellitus 04/2024 - 01/2010
24	Glioblastoma (Glioblastoma Multiforme) 02/2024 - 09/2014
24	Brain Injuries (Brain Injury) 01/2024 - 11/2007
23	Liver Neoplasms (Liver Cancer) 05/2024 - 02/2002
23	Pneumonia (Pneumonitis) 04/2024 - 10/2009
23	Neuroinflammatory Diseases 03/2024 - 04/2016
22	Insulin Resistance 04/2024 - 07/2008
21	Tuberculosis (Tuberculoses) 05/2024 - 11/2006
21	Periodontitis 05/2024 - 02/2013
21	Asthma (Bronchial Asthma) 05/2024 - 01/2003
21	Sepsis (Septicemia) 04/2024 - 03/2010
21	Acute Kidney Injury (Acute Renal Failure) 12/2023 - 01/2013
21	Obesity 04/2023 - 04/2013

Drug/Important Bio-Agent (IBA)

279	Proteins (Proteins, Gene)FDA Link 04/2024 - 05/2002
175	Biomarkers (Surrogate Marker)IBA 04/2024 - 02/2004
102	CytokinesIBA 03/2024 - 09/2002
101	MicroRNAs (MicroRNA)IBA 04/2024 - 01/2009
84	Messenger RNA (mRNA)IBA 03/2024 - 01/2004
57	Therapeutic UsesIBA 05/2024 - 12/2004
57	RNA (Ribonucleic Acid)IBA 04/2024 - 02/2012
57	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 09/2002
45	EnzymesIBA 04/2024 - 09/2005
44	VaccinesIBA 04/2024 - 07/2005
44	Glucose (Dextrose)FDA LinkGeneric 04/2024 - 03/2011
44	Phosphotransferases (Kinase)IBA 01/2023 - 07/2005
42	Long Noncoding RNAIBA 12/2023 - 01/2015
42	Small Interfering RNA (siRNA)IBA 01/2023 - 06/2006
41	LipidsIBA 12/2024 - 01/2006
38	Cisplatin (Platino)FDA LinkGeneric 12/2023 - 08/2008
37	CollagenIBA 11/2023 - 12/2003
36	Transcription Factors (Transcription Factor)IBA 01/2024 - 04/2005
35	Peptides (Polypeptides)IBA 03/2024 - 02/2004
34	AntigensIBA 04/2024 - 09/2004
34	ErbB Receptors (EGF Receptor)IBA 02/2024 - 12/2010
32	Indicators and Reagents (Reagents)IBA 01/2024 - 03/2005
31	AntioxidantsIBA 04/2024 - 09/2013
31	Antiviral Agents (Antivirals)IBA 04/2024 - 07/2005
30	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2022 - 05/2004
29	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2023 - 09/2002
28	Interleukin-6 (Interleukin 6)IBA 03/2024 - 03/2005
26	HydrogelsIBA 04/2024 - 08/2013
25	Anti-Bacterial Agents (Antibiotics)IBA 05/2024 - 08/2009
25	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2023 - 11/2007
24	AntibodiesIBA 01/2024 - 05/2006
24	LigandsIBA 01/2023 - 06/2006
22	salicylhydroxamic acid (SHAM)IBA 01/2023 - 01/2004
21	Tyrosine Kinase InhibitorsIBA 02/2024 - 05/2011
21	Estrogens (Estrogen)FDA Link 01/2024 - 08/2010
21	Carrier Proteins (Binding Protein)IBA 10/2023 - 08/2005

Therapy/Procedure

312	Therapeutics 05/2024 - 09/2002
141	Drug Therapy (Chemotherapy) 04/2024 - 07/2004
69	Radiotherapy 04/2024 - 01/2008
45	Immunotherapy 05/2024 - 01/2008
42	Neoadjuvant Therapy 02/2024 - 04/2011
29	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2024 - 01/2005
25	Chemoradiotherapy 02/2024 - 12/2010
21	Aftercare (After-Treatment) 12/2023 - 07/2003